NASDAQ:FOLD Amicus Therapeutics (FOLD) Stock Price, News & Analysis $7.35 +0.15 (+2.08%) Closing price 04:00 PM EasternExtended Trading$7.38 +0.03 (+0.34%) As of 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Amicus Therapeutics Stock (NASDAQ:FOLD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Amicus Therapeutics alerts:Sign Up Key Stats Today's Range$7.05▼$7.3850-Day Range$6.48▼$9.8552-Week Range$6.20▼$12.65Volume3.68 million shsAverage Volume2.62 million shsMarket Capitalization$2.26 billionP/E RatioN/ADividend YieldN/APrice Target$16.75Consensus RatingModerate Buy Company OverviewAmicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Read More… Amicus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreFOLD MarketRank™: Amicus Therapeutics scored higher than 82% of companies evaluated by MarketBeat, and ranked 183rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingAmicus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAmicus Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Amicus Therapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth186.67% Earnings GrowthEarnings for Amicus Therapeutics are expected to grow by 186.67% in the coming year, from $0.15 to $0.43 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amicus Therapeutics is -40.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amicus Therapeutics is -40.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioAmicus Therapeutics has a PEG Ratio of 1.51. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmicus Therapeutics has a P/B Ratio of 11.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amicus Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.33% of the float of Amicus Therapeutics has been sold short.Short Interest Ratio / Days to CoverAmicus Therapeutics has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Amicus Therapeutics has recently increased by 6.02%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmicus Therapeutics does not currently pay a dividend.Dividend GrowthAmicus Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.28 Percentage of Shares Shorted6.33% of the float of Amicus Therapeutics has been sold short.Short Interest Ratio / Days to CoverAmicus Therapeutics has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Amicus Therapeutics has recently increased by 6.02%, indicating that investor sentiment is decreasing significantly. News and Social Media3.8 / 5News Sentiment0.91 News SentimentAmicus Therapeutics has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Amicus Therapeutics this week, compared to 6 articles on an average week.Search Interest13 people have searched for FOLD on MarketBeat in the last 30 days. This is an increase of 333% compared to the previous 30 days.MarketBeat Follows3 people have added Amicus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Amicus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,000.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of Amicus Therapeutics is held by insiders.Read more about Amicus Therapeutics' insider trading history. Receive FOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FOLD Stock News HeadlinesTD Cowen Remains a Buy on Amicus (FOLD)April 24 at 5:44 PM | markets.businessinsider.comIs Amicus Therapeutics, Inc. (FOLD) Among the Best Guru Stocks to Buy According to Wall Street Analysts?April 23 at 2:35 PM | insidermonkey.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 25, 2025 | Porter & Company (Ad)Is Amicus Therapeutics, Inc. (FOLD) Among the Best Guru Stocks to Buy According to Wall Street Analysts?April 23 at 2:18 PM | msn.com11 Best Guru Stocks to Buy According to Wall Street AnalystsApril 23 at 8:45 AM | insidermonkey.comAmicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025April 21, 2025 | globenewswire.comBank of America Securities Reaffirms Their Buy Rating on Amicus (FOLD)April 18, 2025 | markets.businessinsider.comIs Amicus Therapeutics, Inc. (FOLD) the Best Low Priced Growth Stock To Invest In?April 11, 2025 | msn.comSee More Headlines FOLD Stock Analysis - Frequently Asked Questions How have FOLD shares performed this year? Amicus Therapeutics' stock was trading at $9.42 at the start of the year. Since then, FOLD stock has decreased by 22.0% and is now trading at $7.35. View the best growth stocks for 2025 here. How were Amicus Therapeutics' earnings last quarter? Amicus Therapeutics, Inc. (NASDAQ:FOLD) released its earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, meeting analysts' consensus estimates of ($0.05). The company's quarterly revenue was up 34.0% on a year-over-year basis. Read the conference call transcript. Who are Amicus Therapeutics' major shareholders? Top institutional investors of Amicus Therapeutics include Peregrine Capital Management LLC (0.30%), Rhumbline Advisers (0.14%), Wedge Capital Management L L P NC (0.05%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Bradley L Campbell, Daphne Quimi, Ellen Rosenberg, Ellen Rosenberg, Jeff Castelli, David Michael Clark, Samantha Prout, Michael Raab and Margaret G Mcglynn. View institutional ownership trends. How do I buy shares of Amicus Therapeutics? Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amicus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amicus Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Walt Disney (DIS), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and Netflix (NFLX). Company Calendar Last Earnings8/08/2024Today4/25/2025Next Earnings (Estimated)5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:FOLD CIK1178879 Webwww.amicusrx.com Phone(215) 921-7600Fax609-662-2001Employees480Year Founded2002Price Target and Rating Average Stock Price Target$16.75 High Stock Price Target$21.00 Low Stock Price Target$12.00 Potential Upside/Downside+127.9%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.18) Trailing P/E RatioN/A Forward P/E Ratio49.00 P/E Growth1.51Net Income$-151,580,000.00 Net Margins-10.62% Pretax Margin-5.44% Return on Equity12.44% Return on Assets2.60% Debt Debt-to-Equity Ratio2.01 Current Ratio3.39 Quick Ratio2.42 Sales & Book Value Annual Sales$528.30 million Price / Sales4.27 Cash FlowN/A Price / Cash FlowN/A Book Value$0.63 per share Price / Book11.67Miscellaneous Outstanding Shares307,240,000Free Float292,232,000Market Cap$2.26 billion OptionableOptionable Beta0.79 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:FOLD) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.